Swab Test Helps Transplant Patients Receive Right Anti-Rejection Medication Dose

Tacrolimus is widely used to prevent organ rejection in transplant recipients, but achieving the correct dose early is critical. If levels are too low, the transplanted organ may be rejected; if too high, patients face risks of infection, toxicity, and other serious complications. Standard dosing often requires repeated adjustments because patients metabolize tacrolimus differently, partly due to genetic variation. Now, a new laboratory-developed pharmacogenetic test is designed to help clinicians make more informed tacrolimus dosing decisions from the outset.

Thermo Fisher Scientific (Waltham, MA, USA) has launched the TacroType Pharmacogenetic Test to support personalized tacrolimus dosing in solid organ transplant recipients. The test analyzes a patient’s CYP3A5 genotype, a key genetic factor that influences how quickly tacrolimus is metabolized and how an individual responds to therapy.

Image: The test helps tailor tacrolimus dosing for transplant recipients based on genetic metabolism profiles (Photo courtesy of Adobe Stock)

Using a simple buccal swab sample, the one-time assessment employs rapid qPCR-based genotyping to provide actionable genetic insights. When performed prior to transplant, the test can help guide initial tacrolimus dosing decisions, complementing ongoing therapeutic drug monitoring rather than replacing it.

The TacroType test identifies genetic differences in CYP3A5 that affect drug metabolism, allowing clinicians to anticipate whether a patient may require higher or lower starting doses. By incorporating pharmacogenetic data early, providers may be able to reduce the trial-and-error adjustments typically required during the vulnerable post-transplant period.

The approach aims to help patients reach target tacrolimus levels more efficiently, potentially lowering the risk of adverse events while supporting long-term graft function and patient outcomes. By moving beyond conventional weight-based dosing strategies, the test introduces a more individualized approach to immunosuppressive therapy.

Early genetic insights can support safer initial dosing, reduce complications, and improve treatment precision during a critical phase of recovery. As pharmacogenetic testing becomes more integrated into transplant care, tools such as TacroType may contribute to broader adoption of precision medicine strategies in solid organ transplantation.

“When patients receive a transplant, every day matters,” said Tina Liedtky, president of the transplant diagnostics business at Thermo Fisher Scientific. “The TacroType test gives clinicians valuable information from the start and supports more effective, personalized care for patients during a critical period. This new test reflects the growing role of pharmacogenetics in transplant medicine. It offers clinicians an additional data point to help manage immunosuppressive therapy to each patient’s unique needs.”

Related Links:
Thermo Fisher Scientific